Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery or the Development stage.  In the Discovery phase the goal is to characterize and optimize promising hit compounds using medicinal chemistry to establish structure activity relationships (SAR) and structure property relationships (SPR) including in vitro and in vivo properties such as metabolism, selectivity, toxicity, etc. As projects enter or advance to the Development stage the goal is to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects can enter the program at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN recipient  Institutions retain their assignment of intellectual property (IP) rights and gain assignment of IP rights from the BPN contractors and consultants (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Companion FOA: PAR-24-063 , U44 Small Business Innovation Research (SBIR) Cooperative Agreements - Fast-Track


  • Letter of Intent Due Date(s): 30 days prior to the application due date 
  • Application Due Date(s): Feb. 9, 2024; July 15, 2024; Jan. 15, 2025; July 15, 2025; Jan 15, 2026; July 15, 2026
  • AIDS Application Due Date(s): April 18, 2024; Aug 18, 2024; April 18, 2025; Aug 18, 2025; April 17, 2026; Aug 18, 2026

PAR-24-043 Expiration Date August 19, 2026

Agency Website

Amount Description


Funding Type





Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 9, 2024